GlobalData: In 2021, Lilly's weight loss drug Zepbound sold $4.1 billion in the United States
qiu539790999
发表于 2023-11-13 17:51:28
4038
0
0
According to a recent report by data analysis company GlobalData, the newly approved weight loss drug Zepbound by American pharmaceutical company Eli Lilly will have sales of $4.1 billion in the United States alone by 2031.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- GLP-1 Weight Loss Drug Production Capacity Warming Up: Lilly builds a factory in Germany for $2.5 billion and is expected to operate in 2027
- Novo Nordisk promises to invest $6 billion to expand production capacity. Prices of weight loss drugs in the United States are expected to further decrease
- American pharmaceutical company Anjin's weight loss pills have attracted attention, and Novo Nordisk's stock price has fallen by 5%
- Earning too much! US Senators indirectly pressure Novo Nordisk to lower the price of weight loss pills
- "Weight loss pills" are sold in limited quantities in China? Novo Nordisk's latest response
- Oral "weight loss medication" further advances Novo Nordisk oral semaglutide weight loss phase III research success
- Lilly weight loss pills are crazily chasing after semaglutide
- Top 20 US stock transactions: Eli Lilly rises over 4%, Biden administration plans to include weight loss drugs in healthcare and subsidy programs
- After more than two years, there is finally no shortage of Zepbound, a weight loss medication from Eli Lilly
- Lilly weight loss pills are now available for purchase on e-commerce platforms. Lilly China responds that they are self funded drugs
